Golgi, trafficking, and mitosis dysfunctions in pulmonary arterial endothelial cells exposed to monocrotaline pyrrole and NO scavenging

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 297, Issue 4, 2009, Pages

  Lee, Jason ^a   Reich, Reuben ^a   Xu, Fang ^a   Sehgal, Pravin B ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

actin; Anterograde and retrograde trafficking; Megalocytosis; Vascular remodeling

Indexed keywords

3,3 BIS(2 AMINOETHYL) 1 HYDROXY 2 OXOTRIAZENE; 4 CARBOXYPHENYL 4,4,5,5 TETRAMETHYLIMIDAZOLINE 1 OXYL 3 OXIDE; ACETYL LOW DENSITY LIPOPROTEIN; ANGIOPOIETIN RECEPTOR; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; C5 CERAMIDE; CAVEOLIN 1; CD31 ANTIGEN; CELL NUCLEUS DNA; CERAMIDE DERIVATIVE; CHOLERA TOXIN B SUBUNIT; CLATHRIN HEAVY CHAIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLUORESCENT DYE; GIANTIN; GOLGI MATRIX 130 PROTEIN; HORSERADISH PEROXIDASE; IMIDAZOLINE DERIVATIVE; INDIRUBIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCROTALINE PYRROLE; N ETHYLMALEIMIDE SENSITIVE FACTOR; NITRIC OXIDE; PROTEIN P165; SCAFFOLD PROTEIN; SCAVENGER; TRANSFERRIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL SECRETION; CELL SIZE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; GENETIC TRANSFECTION; GOLGI COMPLEX; IMAGE ANALYSIS; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; INTERNALIZATION; INTRACELLULAR TRANSPORT; MEGALOCYTOSIS; MITOSIS INHIBITION; NITROSYLATION; NONHUMAN; POLYPLOIDY; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN LOCALIZATION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RECEPTOR DENSITY;

ALKYLATING AGENTS; ANIMALS; CATTLE; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; GOLGI APPARATUS; MICROSCOPY, FLUORESCENCE; MITOSIS; MONOCROTALINE; NITRIC OXIDE; PROTEIN TRANSPORT; PULMONARY ARTERY; SUBCELLULAR FRACTIONS;

EID: 70349758332     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00086.2009     Document Type: Article

References (70)

1. Afzelius BA, Schoental R. The ultrastructure of the enlarged hepatocytes induced in rats with a single oral dose of retrorsine, a pyrrolozidine (Senecio) alkaloid. J Ultrastruct Res 20: 328-345, 1967.
2. Arcot SS, Lipke DW, Gillespie MN, Olson JW. Alterations of growth factor transcripts in rat lungs during development of monocrotaline-induced pulmonary hypertension. Biochem Pharmacol 46: 1086-1091, 1993.
3. Bonifacino JS, Glick BS. The mechanism of vesicle budding and fusion. Cell 116: 153-166, 2004.
4. Bloch KD, Ichinose F, Roberts JD Jr, Zapol WM. Inhaled NO as a therapeutic agent. Cardiovasc Res 75: 339-348, 2007.
5. Bromberg J, Wang TC. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 15: 79-80, 2009.
6. Bull LA. The histological evidence of liver damage from pyrrolizidine alkaloids. Aust Vet J 31: 33-40, 1955.
7. Campbell AIM, Kuliszewski MA, Stewart DJ. Cell-based gene transfer to the pulmonary vasculature: endothelial nitric oxide synthase overexpression inhibits monocrotaline-induced pulmonary hypertension. Am J Respir Cell Mol Biol 21: 567-575, 1999.
8. Coggins MP, Bloch KD. Nitric oxide in the pulmonary vasculature. Arterioscler Thromb Vasc Biol 27: 1877-1885, 2007.
9. Connolly CN, Futter CE, Gibson A, Hopkins CR, Cutler DF. Transport into and out of the Golgi complex studied by transfecting cells with cDNAs encoding horseradish peroxidase. J Cell Biol 127: 641-652, 1994. (Pubitemid 24332962)
10. Gaston B, Singel D, Doctor A, Stamler JS. S-nitrosothiol signaling in respiratory biology. Am J Respir Crit Care Med 173: 1186-1193, 2006.
11. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in lungs of patients with pulmonary hypertension. N Engl J Med 333: 214-221, 1995.
12. Gillis CN, Huxtable RJ, Roth RA. Effects of monocrotaline pretreatment of rats on removal of 5-hydroxytryptamine and noradrenaline by perfused lung. Br J Pharmacol 63: 435-443, 1978. (Pubitemid 8373722)
13. Girgis RE, Champton HC, Diette GB, Johns RA, Permutt S, Sylvester JT. Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy. Am J Respir Crit Care Med 172: 352-357, 2005. (Pubitemid 41026146)
14. Golemski SM, West J, Tada Y, Fagan KA. Interleukin-6 causes mild pulmonary hypertension and augments hypoxia-induced pulmonary hypertension in mice. Chest 128: 572S-573S, 2005. (Pubitemid 43054124)
15. Hagen M, Fagan K, Steudel W, Carr M, Kirk K, Rodman DM, West J. Interaction of interleukin-6 and the BMP pathway in pulmonary smooth muscle. Am J Physiol Lung Cell Mol Physiol 292: L1473-L1479, 2007. (Pubitemid 47077364)
16. Harris PN, Anderson RC, Chen KK. The action of senecionine, integerrimine, jacobine, longilobine, and spartiodine, especially on the liver. J Pharmacol Exp Ther 75: 60-77, 1942.
17. Hill LL, Pearl RG. Combined inhaled nitric oxide and inhaled prostacyclin during experimental chronic pulmonary hypertension. J Appl Physiol 86: 1160-1164, 1999. (Pubitemid 29172146)
18. Hoorn CM, Roth RA. Monocrotaline pyrrole alters DNA, RNA and protein synthesis in pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol 262: L740-L747, 1992.
19. Horstman DJ, Frank DU, Rich GF. Prolonged inhaled NO attenuates hypoxic, but not monocrotaline-induced, pulmonary vascular remodeling in rats. Anesth Analg 86:74-81, 1997.
20. Huxtable RJ. Activation and pulmonary toxicity of pyrrolizidene alkaloids. Pharmac Ther 47: 371-389, 1990.
21. Jansenn YM, Soultanakis R, Steece K, Heerdt E, Singh RJ, Joseph J, Kalyanaraman B. Depletion of nitric oxide causes cell cycle alterations, apoptosis and oxidative cells in pulmonary cells. Am J Physiol Lung Cell Mol Physiol 275: L1100-L1109, 1998. (Pubitemid 29029111)
22. Kang-Decker N, Cao S, Chatterjee S, Yao J, Egan LJ, Semela D, Mukhopadhyay D, Shah V. Nitric oxide promotes endothelial cell survival signaling through S-nitrosylation and activation of dynamin-2. J Cell Sci 120: 492-501, 2007. (Pubitemid 46332512)
23. Klinger JR. The nitric oxide/cGMP signaling pathway in pulmonary hypertension. Clin Chest Med 28: 143-167, 2007. (Pubitemid 46343758)
24. Lalich JJ, Merkow L. Pulmonary arteritis produced in rat by feeding Crotalaria spectabilis. Lab Invest 10: 744-750, 1961.
25. Lamé MW, Jones AD, Wilson DW, Dunston SK, Segall HJ. Protein targets of monocrotaline pyrrole in pulmonary arterial endothelial cells. J Biol Chem 275: 29091-29099, 2000. (Pubitemid 30704251)
26. Lamé MW, Jones AD, Wilson DW, Segall HJ. Monocrotaline pyrrole targets proteins with and without cysteine residues in the cytosol and membrane of human pulmonary arterial endothelial cells. Proteomics 5: 4398-43413, 2005.
27. Lappin PB, Ross KL, King LE, Fraker PJ, Roth RA. The response of pulmonary vascular endothelial cells to monocrotaline pyrrole: cell proliferation and DNA synthesis in vitro and in vivo. Toxicol Appl Pharmacol 150: 37-48, 1998.
28. Lappin PB, Roth RA. Hypertrophy and prolonged DNA synthesis in smooth muscle cells characterize pulmonary arterial wall thickening after monocrotaline pyrrole administration to rats. Toxicol Pathol 25: 372-380, 1997.
29. Malerba M, Radaeli A, Ragnoli B, Airo P, Corradi M, Ponticiello A, Zambruni A, Grassi V. Exhaled nitric oxide levels in systemic sclerosis with and without pulmonary hypertension. Chest 132: 575-580, 2007. (Pubitemid 47282391)
30. Mathew R, Huang J, Shah M, Patel K, Gewitz M, Sehgal PB. Disruption of endothelial-cell caveolin-1α/raft scaffolding during development of monocrotaline-induced pulmonary hypertension. Circulation 110: 1499-1506, 2004. (Pubitemid 39238030)
31. Maruyama J, Maruyama K, Mitani Y, Kitabatake M, Yamauchi T, Miyasaka K. Continuous low-dose NO inhalation does not prevent monocrotaline-induced pulmonary hypertension in rats. Am J Physiol Heart Circ Physiol 272: H517-H524, 1997. (Pubitemid 27066715)
32. Mattocks AR, Jukes R, Brown J. Simple procedures for preparing putative toxic metabolites of pyrrolizidine alkaloids. Toxicon 27: 561-567, 1989. (Pubitemid 19121751)
33. Mattocks AR, Legg RF. Antimitotic activity of dehydroretrorcine, a pyrrolizidine alkaloid metabolite, and some analogous compounds, in a rat liver parenchymal cell line. Chem Biol Interact 30: 325-336, 1980.
34. Merkow L, Kleinerman J. An electron microscopic study of pulmonary vasculitis induced by monocrotaline. Lab Invest 15: 547-564, 1966.
35. Meyrick BO, Gamble W, Reid LM. Development of Crotolaria pulmonary hypertension. Am J Physiol Heart Circ Physiol 239: H692-H702, 1980.
36. 3H-thymidine by the cells of the pulmonary circulation and alveolar walls. Am J Pathol 106: 84-94, 1982.
37. Mukherjee S, Shields D. Nuclear import is required for the pro-apoptotic function of the Golgi protein p115. J Biol Chem 284: 1709-1717, 2009.
38. Mukhopadhyay S, Lee J, Sehgal PB. Depletion of the ATPase NSF from Golgi membranes with hypo-S-nitrosylation of vasorelevatnt proteins in endothelial cells exposed to monocrotaline pyrrole. Am J Physiol Heart Circ Physiol 295: H1943-H1955, 2008.
39. Mukhopadhyay S, Sehgal PB. Discordant regulatory changes in monocrotaline- induced megalocytosis of lung arterial endothelial and alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 290: L1216-L1226, 2006. (Pubitemid 43830867)
40. Mukhopadhyay S, Shah M, Patel K, Sehgal PB. Monocrotaline pyrrole-induced megalocytosis of lung and breast epithelial cells: disruption of plasma membrane and Golgi dynamics and an enhanced unfolded protein response. Toxicol Appl Pharmacol 211: 209-220, 2006.
41. Mukhopadhay S, Shah M, Xu F, Patel K, Tuder RM, Sehgal PB. Cytoplasmic provenance of STAT3 and PY-STAT3 in endolysosomal compartments in pulmonary arterial endothelial and smooth muscle cells: implications in PAH. Am J Physiol Lung Cell Mol Physiol 294: L449-L468, 2008.
42. Mukhopadhyay S, Xu F, Sehgal PB. Aberrant cytoplasmic sequestration of eNOS in endothelial cells after monocrotaline, hypoxia and senescence: subcellular eNOS localization and live-cell caveolar and cytoplasmic NO imaging studies. Am J Physiol Heart Circ Physiol 293: H77-H85, 2007.
43. Nam S, Buettner R, Turkson J, Kim D, Cheng JQ, Muehlbeyer S, Hippe F, Vatter S, Merz KH, Eisenbrand G, Jove R. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci USA 102: 5998-6003, 2005. (Pubitemid 40594244)
44. Nishimura T, Vaszar LT, Faul JL, Zhao G, Berry GJ, Shi L, Qiu D, Benson G, Pearl RG, Kao PN. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 108: 1640-1645, 2003. (Pubitemid 37187793)
45. Pagano RE, Sleight RG. Defining lipid transport pathways in animal cells. Science 229: 1051-1057, 1985.
46. Rabinovitch M. Molecular pathogenesis of pulmonary hypertension. J Clin Invest 118: 2372-2379, 2008.
47. Rai PR, Cool CD, King JAC, Stevens T, Burns N, Winn RA, Kasper M, Voelkel NF. The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 178: 558-564, 2008.
48. Reindel JF, Hoorn CM, Wagner JG, Roth RA. Comparison of response of bovine and porcine pulmonary arterial endothelial cells to monocrotaline pyrrole. Am J Physiol Lung Cell Mol Physiol 261: L406-L414, 1991.
49. Reindel JF, Roth RA. The effects of monocrotaline pyrrole on cultured bovine pulmonary artery endothelial and smooth muscle cells. Am J Pathol 138: 707-719, 1991.
50. Roberts JD Jr, Chiche JD, Weiman J, Steudel W, Zapol WM, Bloch KD. Nitric oxide inhalation decreases pulmonary artery remodeling in the injured lungs of rat pups. Circ Res 87: 140-145, 2000. (Pubitemid 30616910)
51. Sarkar R, Gordon D, Stanley JC, Webb RC. Cell cycle effecte of nitric oxide on vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 272: H1810-H1818, 1997. (Pubitemid 27197885)
52. Sehgal PB. Interleukin 6 in infection and cancer. Proc Soc Exp Biol Med 195: 183-191, 1990.
53. Sehgal PB, Mukhopadhyay S. Dysfunctional intracellular trafficking in the pathobiology of pulmonary arterial hypertension. Am J Respir Cell Mol Biol 37: 31-37, 2007. (Pubitemid 46999534)
54. Sehgal PB, Mukhopadhyay S. Pulmonary hypertension: a disease of tethers, SNAREs and SNAPs? Am J Physiol Heart Circ Physiol 293: H77-H85, 2007.
55. Sehgal PB, Mukhopadhyay S, Patel K, Xu F, Almodovar S, Tuder RM, Flores SC. Golgi dysfunction is a common feature in idiopathic human pulmonary hypertension and vascular lesions in SHIV-nef-infected macaques. Am J Physiol Lung Cell Mol Physiol (July 31, 2009). doi:10.1152/ajplung.00087.2009.
56. Sehgal PB, Mukhopadhyay S, Xu F, Patel K, Shah M. Dysfunction of Golgi tethers, SNAREs and SNAPs in monocrotaline-induced pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 292: L1526-L1542, 2007. (Pubitemid 47077370)
57. Shah M, Patel K, Mukhopadhyay S, Xu F, Guo G, Sehgal PB. Membrane associated STAT3 and PY-STAT3 in the cytoplasm. J Biol Chem 281: 7302-7308, 2006. (Pubitemid 43847498)
58. Shah M, Patel K, Sehgal PB. Monocrotaline pyrrole-induced endothelial cell megalocytosis involves a Golgi blockade mechanism. Am J Physiol Cell Physiol 288: C850-C862, 2005. (Pubitemid 40395063)
59. Shao C, Furusawa Y, Aoki. Sper/NO-induced reversible proliferation inhibition and cycle arrests associated with a micronucleus induction in HSG cells. Nitric Oxide 8: 83-88, 2003. (Pubitemid 36287215)
60. Stow JL, Manderson AP, Murray RZ. SNAREing immunity: the role of SNAREs in the immune system. Nat Rev Immunol 6: 919-929, 2006. (Pubitemid 44851734)
61. Sutterlin C, Hsu P, Mallabiabarrena A, Malhotra V. Fragmentation and dispersal of the pericentriolar Golgi complex is required for entry into mitosis in mammalian cells. Cell 109: 359-369, 2002. (Pubitemid 34606878)
62. Thomas HC, Lamé MW, Wilson DW, Segall HJ. Cell cycle alterations associated with covalent binding of monocrotaline pyrrole to pulmonary artery endothelial cell DNA. Toxicol Appl Pharmacol 141: 319-329, 1996.
63. Tuder RM, Marecki JC, Richter A, Fijalkowska I, Flores S. Pathology of pulmonary hypertension. Clin Chest Med 28: 23-42, 2007.
64. Tyler RC, Muramatsu M, Abman SH, Stelzner TJ, Rodman DM, Bloch KD, McMurtry IF. Variable expression of endothelial NO synthase in three forms of rat pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 276: L297-L303, 1999. (Pubitemid 29102271)
65. Wang Z, Newman WH. Smooth muscle cell migration stimulated by interleukin 6 is associated with cytoskeletal reorganization. J Surg Res 111: 261-266, 2003. (Pubitemid 36808919)
66. White RJ, Meoli DF, Swarthout RF, Kallop DY, Galaria II, Harvey JL, Miller CM, Blaxall BC, Hall CM, Pierce RA, Cool CD, Taubman MB. Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 293: L583-L590, 2007.
67. Wilson DW, Lamé MW, Dunston SK, Segall HJ. DNA damage cell checkpoint activities are altered in monocrotaline pyrrole-induced cell cycle arrest in human pulmonary artery endothelial cells. Toxicol Appl Pharmacol 166: 69-80, 1998.
68. Xu H, Shields D. Prohormone processing in the trans-Golgi network: endoproteolytic cleavage of prostomatin and formation of nascent secretory vesicles in permeabilized cells. J Cell Biol 122: 1169-1184, 1993. (Pubitemid 23277287)
69. Zamanian RT, Haddad F, Doyle RL, Weinacker AB. Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit Care Med 35: 2037-2050, 2007. (Pubitemid 47326439)
70. Zhao YD, Courtman DW, Ng DS, Robb MJ, deng YP, Trogadis J, Han RNN, Stewart DJ. Microvascular regeneration in established pulmonary hypertension by angiogeneic gene transfer. Am J Respir Cell Mol Biol 35: 182-189, 2006.